Allogeneic Hematopoietic Cell Transplant for B-Cell Lymphomas in the Era of Novel Cellular Therapies: Experience from a Tertiary Canadian Center
AlloHCT remains a potentially curative option and should be considered for fit patients with chemosensitive FL or LBCLs of indolent origin and a low comorbidity index.
Authors
- Mathias Castonguay (ORCID: https://orcid.org/0000-0002-9281-8015)
- Jean Roy (ORCID: https://orcid.org/0000-0002-7716-6864)
- Isabelle Fleury (ORCID: https://orcid.org/0000-0002-9301-4748)
- Olivier Veilleux (ORCID: https://orcid.org/0000-0002-7029-1769)
- Imran Ahmad
- Luigina Mollica
- Guy Sauvageau (ORCID: https://orcid.org/0000-0002-4333-7266)
- Silvy Lachance (ORCID: https://orcid.org/0000-0001-7882-9335)
- Denis‐Claude Roy (ORCID: https://orcid.org/0000-0002-5921-1692)
- Nadia M. Bambace
- Jean‐Sébastien Delisle (ORCID: https://orcid.org/0000-0003-1460-7287)
- Jean‐Sébastien Claveau (ORCID: https://orcid.org/0000-0003-2638-5773)
- Léa Bernard
- Sandra Cohen (ORCID: https://orcid.org/0000-0002-0727-4245)
- Thomas Kiss
Institutions
- Hôpital Maisonneuve-Rosemont (CA)
- Université de Montréal (CA)
Publication Details
- Journal
- Current Oncology
- Published
- 2025-05-20
- DOI
- https://doi.org/10.3390/curroncol32050285
- Citations
- 1
- Primary Topic
- Lymphoma Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 1.47